Development Level

Tbio 59 | 10,625
Tchem 25 | 1,890
Tdark 9 | 7,003
Tclin 3 | 602

Collection

Kinase: IDG Consortium (Complete/Control) 1 | 37

IMPC Phenotype

decreased total body fat amoun... 4 | 186
abnormal behavior 3 | 226
increased circulating alkaline... 3 | 119
preweaning lethality, complete... 3 | 633
preweaning lethality, incomple... 3 | 260
tremors 3 | 34
abnormal bone structure 2 | 131
abnormal cornea morphology 2 | 24
abnormal gait 2 | 51
abnormal vibrissa morphology 2 | 17
decreased T cell number 2 | 31
decreased bone mineral content 2 | 157
decreased circulating glucose ... 2 | 121
decreased circulating triglyce... 2 | 83
decreased lean body mass 2 | 195
increased NK cell number 2 | 19
increased body weight 2 | 42
increased circulating free fat... 2 | 17
abnormal digit morphology 1 | 13
abnormal heart left ventricle ... 1 | 20
abnormal response to tactile s... 1 | 16
abnormal retina morphology 1 | 100
abnormal retinal pigmentation 1 | 61
abnormal skin condition 1 | 6
abnormal sleep behavior 1 | 63
abnormal whole-body plethysmog... 1 | 4
convulsive seizures 1 | 11
decreased CD4-positive, CD25-p... 1 | 24
decreased CD8-positive, alpha-... 1 | 26
decreased IgE level 1 | 3
decreased IgG1 level 1 | 4
decreased KLRG1+ CD8 alpha bet... 1 | 8
decreased NK T cell number 1 | 28
decreased blood urea nitrogen ... 1 | 31
decreased body weight 1 | 174
decreased bone mineral density 1 | 126
decreased caudal vertebrae num... 1 | 49
decreased circulating HDL chol... 1 | 77
decreased circulating LDL chol... 1 | 37
decreased circulating alanine ... 1 | 53
decreased circulating alkaline... 1 | 41
decreased circulating amylase ... 1 | 24
decreased circulating aspartat... 1 | 27
decreased circulating choleste... 1 | 85
decreased circulating fructosa... 1 | 31
decreased circulating insulin ... 1 | 75
decreased circulating phosphat... 1 | 15
decreased circulating serum al... 1 | 79
decreased circulating sodium l... 1 | 18
decreased dendritic cell numbe... 1 | 3
decreased grip strength 1 | 123
decreased hemoglobin content 1 | 53
decreased immature NK cell num... 1 | 1
decreased leukocyte cell numbe... 1 | 54
decreased mature B cell number 1 | 25
decreased mean corpuscular hem... 1 | 34
decreased mean corpuscular hem... 1 | 19
decreased mean corpuscular vol... 1 | 50
decreased pulmonary respirator... 1 | 4
decreased thermal nociceptive ... 1 | 4
enlarged heart 1 | 111
enlarged lymph nodes 1 | 27
improved glucose tolerance 1 | 56
increased CD4-positive, alpha ... 1 | 15
increased KLRG1-positive NK ce... 1 | 9
increased Ly6C high monocyte n... 1 | 12
increased blood urea nitrogen ... 1 | 44
increased body length 1 | 20
increased bone mineral density 1 | 52
increased cardiac muscle contr... 1 | 5
increased circulating calcium ... 1 | 32
increased circulating phosphat... 1 | 24
increased circulating total pr... 1 | 20
increased effector memory CD4-... 1 | 15
increased effector memory CD8-... 1 | 14
increased lean body mass 1 | 107
increased leukocyte cell numbe... 1 | 37
increased mature B cell number 1 | 12
increased mature NK cell numbe... 1 | 1
increased monocyte cell number 1 | 27
increased or absent threshold ... 1 | 128
increased plasmacytoid dendrit... 1 | 1
increased thermal nociceptive ... 1 | 9
increased tidal volume 1 | 1
increased total body fat amoun... 1 | 57
limb grasping 1 | 35
male infertility 1 | 62
polydactyly 1 | 22
short tibia 1 | 82

Disease

ovarian cancer 55 | 8,491
osteosarcoma 51 | 7,933
medulloblastoma, large-cell 47 | 6,234
glioblastoma 45 | 5,572
psoriasis 36 | 6,685
Cancer 35 | 2,346
atypical teratoid / rhabdoid tumor 29 | 4,369
lung cancer 29 | 4,473
primitive neuroectodermal tumor 28 | 3,031
pediatric high grade glioma 27 | 2,712
Carcinoma 25 | 2,147
ependymoma 25 | 2,514
pilocytic astrocytoma 25 | 3,086
intraductal papillary-mucinous carcinoma (IPMC) 22 | 2,988
oligodendroglioma 22 | 2,849
subependymal giant cell astrocytoma 22 | 2,287
non-small cell lung cancer 20 | 2,798
astrocytoma 19 | 1,493
group 4 medulloblastoma 19 | 1,875
malignant mesothelioma 19 | 3,163
intraductal papillary-mucinous neoplasm (IPMN) 18 | 3,289
invasive ductal carcinoma 18 | 2,950
lung adenocarcinoma 18 | 2,714
lung carcinoma 18 | 2,844
intraductal papillary-mucinous adenoma (IPMA) 17 | 2,956
ulcerative colitis 17 | 2,087
Pick disease 16 | 1,893
astrocytic glioma 16 | 2,241
medulloblastoma 16 | 1,524
Breast cancer 15 | 3,098
adult high grade glioma 15 | 2,148
pancreatic cancer 15 | 2,300
Alzheimer's disease 14 | 644
group 3 medulloblastoma 14 | 2,254
pituitary cancer 14 | 1,972
Multiple myeloma 12 | 1,327
breast carcinoma 12 | 1,614
diabetes mellitus 12 | 1,663
atypical teratoid/rhabdoid tumor 11 | 1,095
ductal carcinoma in situ 11 | 1,745
primary pancreatic ductal adenocarcinoma 10 | 1,271
tuberculosis 10 | 1,563
Rheumatoid Arthritis 9 | 1,170
colon cancer 9 | 1,475
cystic fibrosis 9 | 1,670
posterior fossa group B ependymoma 9 | 1,530
Asthma 8 | 349
Multiple Sclerosis 8 | 498
Neurodegenerative disease 8 | 383
Waldenstrons macroglobulinemia 8 | 764
acute quadriplegic myopathy 8 | 1,157
spina bifida 8 | 1,064
Endometriosis 7 | 535
Neuropathy 7 | 210
acute myeloid leukemia 7 | 785
aldosterone-producing adenoma 7 | 664
cutaneous lupus erythematosus 7 | 1,056
Amyotrophic Lateral Sclerosis 6 | 432
Arthritis 6 | 248
Down syndrome 6 | 548
Intellectual disability 6 | 573
adrenocortical carcinoma 6 | 1,427
interstitial cystitis 6 | 2,299
mucosa-associated lymphoid tissue lymphoma 6 | 480
pancreatic ductal adenocarcinoma liver metastasis 6 | 1,795
posterior fossa group A ependymoma 6 | 1,511
progressive supranuclear palsy 6 | 674
Inflammatory bowel disease 5 | 142
Neoplastic Cell Transformation 5 | 81
Prostatic Neoplasms 5 | 471
Schizophrenia 5 | 503
dermatomyositis 5 | 966
gastric cancer 5 | 436
glioblastoma multiforme 5 | 347
hepatocellular carcinoma 5 | 550
sonic hedgehog group medulloblastoma 5 | 1,482
Aarskog-Scott syndrome 4 | 11
Atopic dermatitis 4 | 944
Brain Ischemia 4 | 87
Brain disease 4 | 84
Cerebrovascular disease 4 | 231
Crohn's disease 4 | 304
Lung disease 4 | 136
Parkinson's disease 4 | 364
Peripheral T-cell lymphoma 4 | 24
Primary cutaneous T-cell lymphoma 4 | 29
Renal Cell Carcinoma 4 | 199
Reperfusion Injury 4 | 84
Toxic encephalopathy 4 | 131
Vascular disease 4 | 281
hereditary spastic paraplegia 4 | 313
nasopharyngeal carcinoma 4 | 1,056
pancreatic carcinoma 4 | 567
Diabetes Mellitus, Non-Insulin-Dependent 3 | 161
Polycystic Ovary Syndrome 3 | 334
esophageal adenocarcinoma 3 | 737
gastric carcinoma 3 | 832
inflammatory breast cancer 3 | 404
juvenile dermatomyositis 3 | 1,189
tuberculosis and treatment for 6 months 3 | 686

Tissue

Blood and immune system 96 | 17,994
Cardiovascular System 96 | 17,957
Digestive Tract 96 | 18,472
Endocrine System 96 | 18,511
Female tissues 96 | 18,646
Liver and Pancreas 96 | 18,135
Male tissues 96 | 17,968
Nervous System 96 | 18,560
Respiratory system 95 | 17,483
Skin and soft tissues 95 | 18,114
Urinary Tract 95 | 18,443

Target Family

Non-IDG 71 | 11,969
Enzyme 11 | 4,146
Kinase 8 | 634
Epigenetic 3 | 242
Transcription Factor 2 | 1,400
TF/Epigenetic 1 | 38

Reactome Pathway

p75 NTR receptor-mediated sign... 96 | 96
Signal Transduction 2,515 | 2,515
Immune System 2,183 | 2,183
Metabolism 2,131 | 2,131
Gene Expression 1,754 | 1,754
Metabolism of proteins 1,544 | 1,544
Innate Immune System 1,375 | 1,375
Signaling by GPCR 1,329 | 1,329
Developmental Biology 1,028 | 1,028
GPCR downstream signaling 1,015 | 1,015
Post-translational protein mod... 1,004 | 1,004
Adaptive Immune System 938 | 938
Disease 855 | 855
Generic Transcription Pathway 852 | 852
Cytokine Signaling in Immune s... 803 | 803
Metabolism of lipids and lipop... 797 | 797
Vesicle-mediated transport 705 | 705
Hemostasis 669 | 669
Transmembrane transport of sma... 668 | 668
Membrane Trafficking 608 | 608
Cell Cycle 572 | 572
Neutrophil degranulation 542 | 542
Axon guidance 541 | 541
Signaling by Interleukins 500 | 500
Cell Cycle, Mitotic 470 | 470
Signalling by NGF 467 | 467
GPCR ligand binding 456 | 456
Gastrin-CREB signalling pathwa... 435 | 435
Class I MHC mediated antigen p... 430 | 430
Olfactory Signaling Pathway 430 | 430
Fc epsilon receptor (FCERI) si... 423 | 423
Cellular responses to stress 415 | 415
DAP12 interactions 409 | 409
Infectious disease 391 | 391
NGF signalling via TRKA from t... 378 | 378
Signaling by Rho GTPases 378 | 378
Signaling by PDGF 367 | 367
Diseases of signal transductio... 359 | 359
Transcriptional Regulation by ... 356 | 356
Signaling by EGFR 355 | 355
Metabolism of amino acids and ... 353 | 353
DAP12 signaling 346 | 346
Downstream signal transduction 343 | 343
Neuronal System 343 | 343
Organelle biogenesis and maint... 334 | 334
Signaling by VEGF 329 | 329
Signaling by SCF-KIT 327 | 327
Class A/1 (Rhodopsin-like rece... 322 | 322
VEGFA-VEGFR2 Pathway 321 | 321
FCERI mediated MAPK activation 316 | 316
Signaling by Insulin receptor 312 | 312
Antigen processing: Ubiquitina... 301 | 301
Extracellular matrix organizat... 292 | 292
Signaling by Type 1 Insulin-li... 290 | 290
Signaling by Wnt 290 | 290
IGF1R signaling cascade 289 | 289
IRS-related events triggered b... 289 | 289
Insulin receptor signalling ca... 288 | 288
Metabolism of carbohydrates 288 | 288
DNA Repair 286 | 286
IRS-mediated signalling 285 | 285
MAPK family signaling cascades 283 | 283
Asparagine N-linked glycosylat... 282 | 282
Signaling by the B Cell Recept... 282 | 282
SLC-mediated transmembrane tra... 280 | 280
Deubiquitination 277 | 277
Interferon Signaling 275 | 275
Platelet activation, signaling... 274 | 274
NCAM signaling for neurite out... 268 | 268
M Phase 266 | 266
Interleukin-3, 5 and GM-CSF si... 262 | 262
RET signaling 261 | 261
Signalling to ERKs 254 | 254
Interleukin-2 signaling 253 | 253
Immunoregulatory interactions ... 252 | 252
RHO GTPase Effectors 249 | 249
VEGFR2 mediated cell prolifera... 249 | 249
Signalling to RAS 247 | 247
Interleukin receptor SHC signa... 246 | 246
G alpha (i) signalling events 245 | 245
Fatty acid, triacylglycerol, a... 244 | 244
Signaling by Leptin 244 | 244
Prolonged ERK activation event... 243 | 243
MAPK1/MAPK3 signaling 242 | 242
Frs2-mediated activation 241 | 241
HIV Infection 241 | 241
ARMS-mediated activation 240 | 240
Signalling to p38 via RIT and ... 240 | 240
Chromatin modifying enzymes 237 | 237
Chromatin organization 237 | 237
GRB2 events in EGFR signaling 236 | 236
RAF/MAP kinase cascade 236 | 236
SHC1 events in EGFR signaling 236 | 236
SOS-mediated signalling 236 | 236
Processing of Capped Intron-Co... 235 | 235
Biological oxidations 215 | 215
Keratinization 213 | 213
Transmission across Chemical S... 210 | 210
rRNA processing 209 | 209
Ion channel transport 204 | 204
Phospholipid metabolism 202 | 202

This is where graphics are reside..
Name Gene Development Level Target Family Log Novelty  Pubmed Score  Antibody Count  Knowledge Availability 
Bcl-2-like protein 11 BCL2L11 Tbio Non-IDG -3.14287 1340.6 903
A-kinase anchor protein 13 AKAP13 Tbio Enzyme -2.43559 267.5 129
Proto-oncogene vav VAV1 Tchem Non-IDG -2.64007 465.9 479
Protein kinase C iota type PRKCI Tchem Kinase -1.69816 51.8 122
Guanine nucleotide exchange factor VAV2 VAV2 Tbio Non-IDG -1.78476 58.3 173
Rho guanine nucleotide exchange factor 15 ARHGEF15 Tdark Non-IDG -0.82525 6.56 21
Rho guanine nucleotide exchange factor 9 ARHGEF9 Tbio Non-IDG -1.44935 32.0 102
Rho GDP-dissociation inhibitor 1 ARHGDIA Tchem Non-IDG -2.55630 360.5 330
Ras-related C3 botulinum toxin substrate 1 RAC1 Tbio Enzyme -1.87449 73.5 395
Rho guanine nucleotide exchange factor 12 ARHGEF12 Tbio Non-IDG -2.62041 422.9 86